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Purpose/Objective: Ependymoma is the third most common 
primary brain tumor in children. Radiotherapy is 
systematically delivered after surgery. However, more than a 
third of children experience relapse locally or around the 
resection cavity wall.  
One important factor influencing clinical outcome after 
radiotherapy is the reduced oxygen levels (hypoxia). Major 
noninvasive technique suggested as capable of monitoring 
tumour hypoxia involves MR, and includes both perfusion MRI 
(by dynamic contrast-enhanced MRI, DCE) and diffusion-
weighted imaging (DWI).  
The aim of this study was to investigate if DCE or DWI MRI can 
predict radiotherapy outcome in pediatric ependymoma by 
identification of significant hypoxic subvolumes of tumors 
related to treatment outcomes and that resistance resulting 
from this hypoxia can be overcome by increasing radiation 
dose. 
Materials and Methods: 197 patients were included in this 
national retrospective study, performed in 11 french 
reference centers for pediatric radiation oncology. All 
patients underwent surgical resection and postoperative 
radiochimiotherapy. Imaging data from 93 patients could be 
retrieved. Among them eleven patients had DCE MRI and 
fifteen had DWI MRI at pre radiotherapy exam. All image 
analyses were completed using an in-house software package: 
Sisyphe. For each patient, the resection cavity was 
delineated on the post contrast T1WI. The resulting Region of 
interest (ROI) was mapped to the coregistered CBV and ADC 
map. An histogram analysis was done to determine for both 
CBV and ADC the best fitting of the data hitogramm with 2 or 
3 Gaussian functions. According to the fitting results, the 
cavity ROI was then partitioned into 2 or 3 spatial subvolumes 
using an automatic clustering method (Isodata algorithm). 
Each subvolume with the lower CBV or lower ADC was 
normalized to the ROI volume and evaluated for its 
association with outcome. 
Results: The percentage of the subvolumes with low ADC, 
was not signi?cantly different between the patients with 
Local Failure (LF) and local control (LC) (p = 0.9). The 
percentage of the subvolumes with low CBV, were 
signi?cantly greater, in the patients with LF than with LC ( p 
= 0.025). The ROC analysis indicates that for a subvolume of 
69 % of the volume ROI with low CBV had greater speci?city 
for prediction of local failure (specificity =80%, 
sensibility=100%). 
Conclusions: In our study perfusion MRI was a predictive 
factor of radiotherapy outcome in pediatric ependymoma. 
This is a promising finding as radio resistance resulting from 
hypoperfusion and consequent hypoxia could be overcome by 
increasing radiation dose to the poorly perfused defined 
subvolumes. Confirmation of our imaging data is in progress 
with completion of our database that will allow to present 
our final results to the meeting.  
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Purpose/Objective: to investigate the influence on Event 
free survival ( EFS) and overall survival ( OS ) of main 
characteristics of patients, disease and treatments for 
pediatric patients with localised ependymoma in a national 
cohort 
Materials and Methods: A total of 177 patients with newly 
diagnosed intracranial ependymoma were treated with 
adjuvant Radiation therapy (RT) in the 11 French major 
radiation oncology centers between January 2000 and 
December 2013.  
Clinical data were retrospectively gathered on a web-based 
national database between March and October 2014. 
Results: Location was posterior fossa in 77%, supratentorial 
in 23 %. Anaplastic features were present in 56% of patients. 
The extent of resection was characterized as gross-total in 
86% patients and subtotal in 14%. The median dose to the 
primary site was 59.4 Gy, 37% of patients received a dose ≤54 
Gy. Fifty-one patients received pre-RT chemotherapy. RT was 
3D conformal in 107 patients, IMRT in 60 (of which 18 
tomotherapy) and protontherapy in 10. 
With a median follow up time of 43.1 months from the start 
of RT (95%CI (33,5-52.6)), the 3-years local relapse-free 
survival (LRFS) was 67,8%. Recurrences after RT occurred in 
73 patients (41%) and were mainly local (strictly local in 62% 
of recurrences, local and distant in 7% and strictly distant in 
25%). 
The RT dose significantly influenced overall survival (OS) and 
event-free survival (EFS) after RT. The estimated 3-year OS 
and EFS rates were respectively 90 % and 67% for patients 
who received a dose > 54Gy compared with 79% and 52% for 
patients who received a dose ≤54 Gy (respectively p= 0.008 
and p=0.02). OS and EFS at 3 years were significantly 
improved for patients older than 3 years of age at the 
initiation of RT (92 and 68%) compared to children younger 
than 3 years (71 and 43%) (p=0.0007 and p=0.0001). EFS at 3 
years was greater in grade 1-2 (74%) than in grade 3-4 (53%) 
(p=0.004), OS was also greater in grade 1-2 (97%) than grade 
3-4 (81%) but this was not statistically significant.  
There was no significant difference in OS or EFS regarding the 
quality of surgery, the use of chemotherapy or the technique 
of radiotherapy.  
Conclusions: This large multicentric French cohort confirms 
that a dose > 54 Gy improved survival in localised cerebral 
ependymoma. Age younger than 3 years at initiation of RT 
and grade 3-4 were significant prognostic factors of worse 
outcome. 
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Purpose/Objective: To evaluate feasibility in a multicentric 
setting and clinical results of a RT boost for children with 
Ependymoma and measurable residual disease after first line 
or second look surgery. 
Materials and Methods: The second AIEOP (Italian 
Association of Pediatric Hematology and Oncology) protocol 
for childhood ependymoma opened in 2003. After centralized 
pathological review, children were stratified to receive: 1) 
3D conformal RT or IMRT, 59.4 Gy/33 fractions, to the tumor 
bed in case of complete resection and grade II tumor; 2) 
same RT followed by four cycles of VEC chemotherapy in case 
of complete resection and anaplastic ependymoma; 3) VECx4, 
second look surgery whenever feasible, local RT as in 1) 
followed by a stereotactic hypofractionated (8 Gy/2 
fractions) boost to the residue still measurable after previous 
treatments. 
Results: From 2003, 143 children entered the study (median 
follow-up 60 months). In 24 children (median age 4,5 years, 
15 grade II, 20 infratentorial), out of 46 with residue after 
first surgery, second look wasn't feasible or incomplete and 
thus received VEC and 59.4 Gy to the tumor bed plus 8 Gy to 
the gross residue. 15/24 children are alive without 
progression at a median of 51 months (range 11-120 mos) 
from diagnosis, 5/6 died of local progression at a median of 
20 months, and 3 relapsed distantly, 17-23 months from 
diagnosis, and have died. No iatrogenic death or major 
toxicity occurred. 4 children, irradiated with Tomotherapy, 
developed radiation related MRI changes regressing with 
steroids within 8 months. In the 46 children with residual 
disease, 3 and 5 years PFS was 64% and 55%, and OS 80% and 
68% respectively. 3 and 5-year survival free from local 
relapse was 71% and 64% respectively. 5 year-EFS for children 
receiving the RT boost was 57%. 
Conclusions: Hypofractionated RT boost was feasible and 
contributed to obtain durable local control in 15/24 children 
with measurable residue after first line or second look 
surgery. An aggressive and integrated local treatment 
strategy, multiple surgeries and RT including an 
hypofractionated boost in case of residual disease, is 
required to improve outcome in children with Ependymoma. 
This background will be the basis of the next opening SIOP 
(Société International d'Oncologie Pediatrique) trial for 
Ependymoma.  
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Stereotactic body radiotherapy (SBRT) frequently involves the 
accurate delivery of a few large fractions to a relatively well-
defined target. The favorable anti-tumor characteristics of 
large fractions needs to be balanced against the fact that 
they are often poorly tolerated by normal organs. Although 
this means that SBRT is not possible in all clinical situations, 
in others the risks can be managed in a variety of ways 
including the use of planning and delivery techniques that 
simultaneously facilitate target coverage and organ at risk 
sparing. While the application of extremely hypo-
fractionated radiotherapy to the radical treatment of primary 
tumors is not new, current interest coincides with the 
widespread availability of advanced radiotherapy systems. 
Nonetheless, the successful paradigm of using SBRT to treat 
peripheral, early-stage lung cancer has yet to be replicated 
in other clinical scenarios. Against this background the 
present talk aims to briefly outline the essential features of 
SBRT; describe the historical aspects of extreme hypo-
fractionation for radical treatments; succinctly review the 
current literature on SBRT for treating primary tumors; 
discuss some of the challenges in using SBRT for this 
indication; and touch on future perspectives. 
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Metastases account for approximately 80–90% of cancer 
deaths. Systemic therapies (either cytotoxic chemotherapy or 
targeted agents), the cornerstone for treatment in 
metastatic disease, are rather than curative. Therefore, 
novel therapies for the treatment of patients with metastatic 
cancer are needed. 
In 1995, Hellmann and Weichselbaum coined the term 
“oligometastases” to describe a less-advanced (or 
“intermediate”) state of metastatic disease, peculiarly 
situated between locoregionally-confined and widely-
metastatic cancer. In this paradigm, a limited burden of 
metastatic disease may be amenable to potentially curative 
local therapies.  
Stereotactic Body RadioTherapy (SBRT), which is also 
referred to as Stereotactic Ablative Radiotherapy (SABR), is a 
form of high-precision radiotherapy, tipically delivered in one 
to 8 fractions, commonly using fraction sizes of 7.5 Gy or 
more. SBRT allows for target dose-escalation (thus increasing 
tumor control), while minimizing normal tissue exposure 
(thus minimizing the toxicity risk). When compared to 
surgery, SBRT has the theoretical advantage to be less 
invasive and more effective, because of  lower morbidity 
rates, lower costs and the potential for delivering ablative 
treatments on an outpatient basis. 
